Risk factors for graves’ orbitopathy: A systematic review and meta-analysis
Authors:
- Lidia CheiddeLCLidia Cheidde
- Dillan Cunha AmaralDillan Cunha Amaral
- Yuri Aleksander-IvanovYAYuri Aleksander-Ivanov
- Raynara Pereira CamargoRCRaynara Pereira Camargo
- Arthur Tiemann PaiãoAPArthur Tiemann Paião
- Maria Clara De Campos SalesMSMaria Clara De Campos Sales
- Roberta Andreucci Pereira Gomes GilRGRoberta Andreucci Pereira Gomes Gil
- Pedro Henrique Detoffol Farias PereiraPPPedro Henrique Detoffol Farias Pereira
- Pietra Homem De Mello Assis NunesPNPietra Homem De Mello Assis Nunes
- Ricardo Noguera LouzadaRicardo Noguera Louzada
- 24 July 2026
- journal article
- review article
- Published by SAGE Publications in European Journal of Ophthalmology
Abstract
Introduction: Understanding the modifiable risk factors for Graves’ orbitopathy (GO) is crucial for its prevention. Methods: We searched PubMed, Embase, and Web of Science databases following PRISMA guidelines. Studies reporting the presence of GO compared to patients with Graves’ disease (GD) without orbitopathy or healthy controls were included. Statistical analysis was performed using Review Manager 5.4.1. Results: Twenty-two studies met the inclusion criteria. Smoking increased the risk of GO, with odds ratios (ORs) of 2.00 (95% CI [1.47, 2.72]; p < 0.0001) for current smokers and 1.77 (95% CI [1.33, 2.37]; p = 0.0001) for former smokers, compared with GD patients without orbitopathy. Thyroidectomy was associated with a higher OR of Graves’ disease without orbitopathy, supporting a protective effect against orbitopathy (OR 2.53; 95% CI [1.03, 6.22]; p = 0.04). However, radioiodine therapy did not show a significant association (OR 0.89; 95% CI [0.42, 1.91]; p = 0.77). Biomarkers, including vitamin D ( p = 0.63), FT3 ( p = 0.89), FT4 ( p = 0.59), and TSH ( p = 0.40), showed no significant differences. In comparison to healthy controls, smoking remained a major risk factor for GO (OR 4.81; 95% CI [1.39, 16.70]; p = 0.01), while elevated FT4 (MD 8.87; 95% CI [1.64, 16.10]; p = 0.02) and decreased TSH (MD −1.23; 95% CI [-2.25, −0.20]; p = 0.02) levels were found in the GO groups. Conclusion: Our analysis provides a comprehensive understanding of clinical and biomarker-based risk factors to guide targeted prevention strategies.Keywords
This publication has 45 references indexed in Scilit:
- Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and managementThe Lancet Diabetes & Endocrinology, 2025
- Monocyte-to-high-density lipoprotein ratio and systemic immune-inflammation index: Potential parameters for the evaluation of disease activity and severity in Graves’ ophthalmopathy?International Ophthalmology, 2024
- Thyroid Eye Disease and its Vision-Threatening Manifestations in the Academy IRIS Registry: 2014-2018American Journal of Ophthalmology, 2023
- Absence of a relationship between vitamin D and Graves’ orbitopathyJournal of Endocrinological Investigation, 2023
- Risk Factors of Thyroid Eye DiseaseEndocrine Practice, 2021
- Risk factors for Graves' Orbitopathy in surgical patients—Results of a 10‐year retrospective study with review of the literatureEndocrinology, Diabetes & Metabolism, 2020
- Cardiovascular Outcomes of Thyroidectomy or Radioactive Iodine Ablation for Graves' DiseaseJournal of Surgical Research, 2020
- Relationship between serum cholesterol and Graves’ orbitopathy (GO): a confirmatory studyJournal of Endocrinological Investigation, 2018
- Type 2 diabetic patients with Graves' disease have more frequent and severe Graves' orbitopathyNutrition, Metabolism and Cardiovascular Diseases, 2015
- Immunopathogenesis of Graves’ ophthalmopathy: The role of the TSH receptorBest Practice & Research Clinical Endocrinology & Metabolism, 2012